Answers are grounded in this paper and cite their sources.
Vaccination has been shown to be one of the most powerful tools to decrease morbidity and mortality caused by an array of infectious diseases. The risk and complications of some vaccine-preventable diseases is higher in HIV-infected individuals, underscoring the importance of vaccination in these patients. However, the immune response upon vaccination is generally impaired and shorter lasting in HIV-infected individuals, especially in those with low CD4+ T-lymphocyte counts and detectable HIV RNA, as compared with healthy controls. Even in patients responding to antiretroviral treatment, an impaired immune response may persist despite normalization of the CD4+-cell count. Caution with live-attenuated vaccines is warranted in HIV-infected individuals with low CD4 T-lymphocyte counts. Decisions regarding administering a live-attenuated vaccine should be made after weighing the risks and benefits on an individual basis. In this article the immunology of vaccination in HIV-infected individuals, as well as the most relevant caveats of vaccination in this patient group, are reviewed in addition to the currently available information concerning the influenza A/H1N1 2009 monovalent vaccine.
No takes yet. Share an insight, caveat, or question.
Gelinck et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: